| Trial ID: | L2458 |
| Source ID: | NCT05440591
|
| Associated Drug: |
Dapagliflozin
|
| Title: |
Effects of Dapagliflozin and Metformin on Vascular Function in Newly-Diagnosed Treatment-Naive Type 2 Diabetes
|
| Acronym: |
DMVascular
|
| Status: |
UNKNOWN
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Diabetes
|
| Interventions: |
DRUG: Dapagliflozin|DRUG: MetFORMIN 500 Mg Oral Tablet|DRUG: Dapagliflozin / metFORMIN Pill
|
| Outcome Measures: |
Primary: Endothelial Function measured as reactive hyperaemia index (RHI-EndoPAT), 3 months after initiation|Carotid Femoral Pulse Wave Velocity, Sphygmocor determined cf-PWV, 3 months after initiation | Secondary: Augmentation index, Augmentation index-sphygmocor derived and RHI-endoPAT derived, 3 months after initiation|Central pulse pressure, CPP-Sphygmocor derived, 3 months after initiation|Advanced glycation end products, AGE reader measurements, 3 months after initiation
|
| Sponsor/Collaborators: |
Sponsor: Tan Tock Seng Hospital
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE4
|
| Enrollment: |
150
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2019-04-01
|
| Completion Date: |
2023-05-10
|
| Results First Posted: |
|
| Last Update Posted: |
2022-07-01
|
| Locations: |
Tan Tock Seng Hospital, Singapore, 308433, Singapore
|
| URL: |
https://clinicaltrials.gov/show/NCT05440591
|
